Cargando…

Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography

Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months o...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Sharjeel, Rasheed, Rashid, Marafi, Fahad, Al Kandari, Fareeda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481218/
https://www.ncbi.nlm.nih.gov/pubmed/31040539
http://dx.doi.org/10.4103/ijnm.IJNM_141_18
Descripción
Sumario:Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months of treatment, he developed watery diarrhea and cramping abdominal pain. Follow-up positron emission tomography-computed tomography scan showed complete metabolic resolution of the disease; however, there is bowel wall thickening and colonic distension with corresponding increased fluorodeoxyglucose uptake. These findings are related to immune-related adverse event associated with nivolumab treatment, i.e., secondary enterocolitis. These adverse events can be successfully treated if timely and appropriately diagnosed.